Sua seleção (0)
Detalhe da pesquisa
1.
Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.
Cancer Immunol Immunother;
67(1): 89-100, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28948333
Mostrar mais
Texto completo
Documentos relacionados
2.
Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials.
J Transl Med;
9: 223, 2011 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-22208910
3.
Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells.
Clin Immunol;
133(1): 69-77, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19660988
4.
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
Oncotarget;
6(20): 18192-205, 2015 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26078335
5.
Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia.
Blood;
109(6): 2553-6, 2007 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17090647
6.
In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients.
Clin Immunol;
122(1): 18-27, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17059893
